Spared CA1 Pyramidal Neuron Function and Hippocampal Performance Following Antisense Knockdown of MicroRNA-134

Overview

Journal Epilepsia

Specialty Neurology

Date 2018 Jul 7

PMID 29978460

Citations 11

Authors

Gareth Morris

Gary P Brennan

Cristina R Reschke

David C Henshall

Stephanie Schorge

Affiliations

Soon will be listed here.

Abstract

Objective: Inhibition of microRNA-134 by an oligonucleotide antagomir (ant-134) has been shown to produce powerful antiseizure effects in multiple models of epilepsy. However, to successfully translate the treatment to the clinic, it is important to assess what potential adverse effects it may have on naive brain tissue.

Methods: To investigate this, adult male Sprague-Dawley rats were treated with either ant-134 or a scrambled control sequence. Animals were later assessed for spatial navigation, before ex vivo slices were taken to assess the effects of microRNA-134 knockdown on well-defined measures of intrinsic and synaptic properties.

Results: Hippocampal field potential recordings determined that silencing of microRNA-134 by ant-134 injection was associated with a reduction in epileptiform activity following application of 9 mmol/L K . Nevertheless, rats performed normally in the novel object location test. Action potential waveforms and miniature excitatory synaptic currents recorded in CA1 pyramidal neurons were unaffected by ant-134.

Significance: These results demonstrate that ant-134 confers a seizure-protective effect without obvious interference with hippocampal neuronal properties or network function. These findings support further development of this novel approach to epilepsy treatment.

Citing Articles

Circulating miR-134 in mesial temporal lobe epilepsy: implications in hippocampal sclerosis development and drug resistance.

Guerra Leal B, Carvalho C, Santos C, Samoes R, Martins-Ferreira R, Teixeira C Front Mol Neurosci. 2025; 17:1512860.

PMID: 39744540 PMC: 11688299. DOI: 10.3389/fnmol.2024.1512860.

Pathogenesis, diagnosis, and treatment of epilepsy: electromagnetic stimulation-mediated neuromodulation therapy and new technologies.

Jiao D, Xu L, Gu Z, Yan H, Shen D, Gu X Neural Regen Res. 2024; 20(4):917-935.

PMID: 38989927 PMC: 11438347. DOI: 10.4103/NRR.NRR-D-23-01444.

MicroRNAs: protective regulators for neuron growth and development.

Ma Z, Liu Z, Xiong H, Zhou Z, Ouyang L, Xie F Neural Regen Res. 2022; 18(4):734-745.

PMID: 36204829 PMC: 9700101. DOI: 10.4103/1673-5374.353481.

MicroRNA inhibition using antimiRs in acute human brain tissue sections.

Morris G, Langa E, Fearon C, Conboy K, Lau E-How K, Sanz-Rodriguez A Epilepsia. 2022; 63(8):e92-e99.

PMID: 35656590 PMC: 9546319. DOI: 10.1111/epi.17317.

Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy.

Reschke C, Silva L, Vangoor V, Rosso M, David B, Cavanagh B Mol Ther. 2021; 29(6):2041-2052.

PMID: 33609732 PMC: 8178478. DOI: 10.1016/j.ymthe.2021.02.021.

References

Morris G, Jiruska P, Jefferys J, Powell A . A New Approach of Modified Submerged Patch Clamp Recording Reveals Interneuronal Dynamics during Epileptiform Oscillations. Front Neurosci. 2016; 10:519. PMC: 5101843. DOI: 10.3389/fnins.2016.00519. View

Brodie M, Barry S, Bamagous G, Norrie J, Kwan P . Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012; 78(20):1548-54. PMC: 3348850. DOI: 10.1212/WNL.0b013e3182563b19. View

Gao J, Wang W, Mao Y, Graff J, Guan J, Pan L . A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature. 2010; 466(7310):1105-9. PMC: 2928875. DOI: 10.1038/nature09271. View

Burgess N, Maguire E, OKeefe J . The human hippocampus and spatial and episodic memory. Neuron. 2002; 35(4):625-41. DOI: 10.1016/s0896-6273(02)00830-9. View

Valluy J, Bicker S, Aksoy-Aksel A, Lackinger M, Sumer S, Fiore R . A coding-independent function of an alternative Ube3a transcript during neuronal development. Nat Neurosci. 2015; 18(5):666-73. DOI: 10.1038/nn.3996. View

Miller-Delaney S, Bryan K, Das S, McKiernan R, Bray I, Reynolds J . Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy. Brain. 2015; 138(Pt 3):616-31. PMC: 4408428. DOI: 10.1093/brain/awu373. View

Morris G, Brennan G, Reschke C, Henshall D, Schorge S . Spared CA1 pyramidal neuron function and hippocampal performance following antisense knockdown of microRNA-134. Epilepsia. 2018; 59(8):1518-1526. PMC: 6099438. DOI: 10.1111/epi.14475. View

Jimenez-Mateos E, Engel T, Merino-Serrais P, Fernaud-Espinosa I, Rodriguez-Alvarez N, Reynolds J . Antagomirs targeting microRNA-134 increase hippocampal pyramidal neuron spine volume in vivo and protect against pilocarpine-induced status epilepticus. Brain Struct Funct. 2014; 220(4):2387-99. DOI: 10.1007/s00429-014-0798-5. View

Sirven J, Noe K, Hoerth M, Drazkowski J . Antiepileptic drugs 2012: recent advances and trends. Mayo Clin Proc. 2012; 87(9):879-89. PMC: 3538494. DOI: 10.1016/j.mayocp.2012.05.019. View

10.

Chai S, Cambronne X, Eichhorn S, Goodman R . MicroRNA-134 activity in somatostatin interneurons regulates H-Ras localization by repressing the palmitoylation enzyme, DHHC9. Proc Natl Acad Sci U S A. 2013; 110(44):17898-903. PMC: 3816481. DOI: 10.1073/pnas.1317528110. View

11.

Jimenez-Mateos E, Engel T, Merino-Serrais P, McKiernan R, Tanaka K, Mouri G . Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med. 2012; 18(7):1087-94. PMC: 3438344. DOI: 10.1038/nm.2834. View

12.

Bicker S, Khudayberdiev S, Weiss K, Zocher K, Baumeister S, Schratt G . The DEAH-box helicase DHX36 mediates dendritic localization of the neuronal precursor-microRNA-134. Genes Dev. 2013; 27(9):991-6. PMC: 3656329. DOI: 10.1101/gad.211243.112. View

13.

Wickham J, Brodjegard N, Vighagen R, Pinborg L, Bengzon J, Woldbye D . Prolonged life of human acute hippocampal slices from temporal lobe epilepsy surgery. Sci Rep. 2018; 8(1):4158. PMC: 5841387. DOI: 10.1038/s41598-018-22554-9. View

14.

Henshall D, Hamer H, Pasterkamp R, Goldstein D, Kjems J, Prehn J . MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol. 2016; 15(13):1368-1376. DOI: 10.1016/S1474-4422(16)30246-0. View

15.

Kosik K . The neuronal microRNA system. Nat Rev Neurosci. 2006; 7(12):911-20. DOI: 10.1038/nrn2037. View

16.

Wang X, Jia R, Wei D, Cui W, Jiang W . MiR-134 blockade prevents status epilepticus like-activity and is neuroprotective in cultured hippocampal neurons. Neurosci Lett. 2014; 572:20-5. DOI: 10.1016/j.neulet.2014.04.049. View

17.

Reschke C, Almeida Silva L, Norwood B, Senthilkumar K, Morris G, Sanz-Rodriguez A . Potent Anti-seizure Effects of Locked Nucleic Acid Antagomirs Targeting miR-134 in Multiple Mouse and Rat Models of Epilepsy. Mol Ther Nucleic Acids. 2017; 6:45-56. PMC: 5363384. DOI: 10.1016/j.omtn.2016.11.002. View

18.

Schratt G, Tuebing F, Nigh E, Kane C, Sabatini M, Kiebler M . A brain-specific microRNA regulates dendritic spine development. Nature. 2006; 439(7074):283-9. DOI: 10.1038/nature04367. View

19.

Margineanu D, Klitgaard H . Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res. 2000; 42(4):281-5. DOI: 10.1006/phrs.2000.0689. View

20.

Sun J, Gao X, Meng D, Xu Y, Wang X, Gu X . Antagomirs Targeting MicroRNA-134 Increase Limk1 Levels After Experimental Seizures in Vitro and in Vivo. Cell Physiol Biochem. 2017; 43(2):636-643. DOI: 10.1159/000480647. View